Cash-rich psychedelic stocks are cheap. They are also building value for investors -- at an accelerating rate.
Exploring the companies and themes that make up this emerging and exciting new sector
Numinus Advances Phase 1 Trial on Proprietary Psilocybin Product
Numinus prepares for a Phase I clinical trial of its proprietary psilocybin extract.
Small Pharma Announces Upgrade to the OTCQB® and DTC Eligibility
Small Pharma announces receiving DTC Eligibility and its OTCQB listing to broaden liquidity and increase access for U.S. investors.
COMPASS Pathways is granted new US patent for crystalline psilocybin
Compass Pathway's fourth U.S. patent covers its Form A hydrate psilocybin, and is the first patent for this formulation.
First Patient Dosed in Phase IIa DMT-Assisted Therapy Clinical Trial
Small Pharma commences enrolling patients for its Phase IIa DMT-based clinical trial aimed at treating Major Depressive Disorder.
Levitee Labs Announces Agreement with Adracare, a WELL Health Company, to Support Individuals with Addiction and Mental Health Conditions
Levitee Labs announces a partnership with Adracare Inc., a subsidiary of Well Health Technologies (WELL), to build out a digital therapeutics platform.
Oakland Psychedelics Activists Launch Initiative To Legalize Community-Based Sales With Support From City Council
Oakland activists are hoping to expand upon the city’s current psychedelics decriminalization ordinance by creating a community-based model through which people could legally purchase entheogenic substances from local producers.
Singer Melissa Etheridge And Activist Van Jones Promote Psychedelics Reform As Movement Grows
The fight to end the criminalization of psychedelics and give patients access to natural plants and fungi has achieved success in a growing number of cities and states in recent years, and on Thursday the cause got a boost from prominent people in the entertainment and political fields.
Psychedelic Medicine: The Only Hope In Solving The Mental Health LABOR CRISIS
The "crippling labor shortages" plaguing the U.S. economy are directly attributable to the Mental Health Crisis. Psychedelic medicine is the only answer.
PharmaTher Granted FDA Orphan Drug Designation For Ketamine To Treat Complex Regional Pain Syndrome
PharmaTher receives its second FDA orphan drug designation for a ketamine-based therapy.
Novamind Granted DEA Licenses for Psilocybin Research
Novamind's new DEA licenses open up opportunities to host formal clinical trials.
MindMed Joins Clinical Trials Transformation Initiative
MindMed joins the Clinical Trials Transformation Initiative, a forward-looking healthcare association that develops/promotes new health therapies.